Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Nuo Therapeutics, Inc. | v317518_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2012
Cytomedix, Inc.
(Exact name of registrant as specified in its charter)
______________
| Delaware | 01-32518 | 23-3011702 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |
209 Perry Parkway, Suite 7, Gaithersburg, MD 20877
(Address of Principal Executive Office) (Zip Code)
240-499-2680
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
Attached, as Exhibit 99.1, is the press release issued in connection with the matter set forth under Item 8.01 below. The information in Exhibit 99.1 is not “filed” pursuant to the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any Securities Act registration statements. Additionally, the submission of this report on Form 8-K is not an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD.
Item 8.01 Other Events
On July 2, 2012, Cytomedix, Inc. (the “Company”) issued a press release relating to the extension of the previously announced exclusivity period until August 30, 2012. The press release also provided an update on, among other things, the state of the Company’s dialogue with the Centers for Medicare & Medicaid Services (CMS) and the Company’s negotiations of a distribution agreement with the same partner. There is no assurance that the parties will be successful in executing such a definitive distribution agreement.
Item 9.01 Financial Statement and Exhibits
(d) Exhibits.
99.1 Press release.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Cytomedix, Inc. | ||
| By: | /s/ Martin P. Rosendale | |
|
Martin P. Rosendale Chief Executive Officer | ||
Date: July 2, 2012